## Olaf Schoffer

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/920120/publications.pdf

Version: 2024-02-01

687363 610901 31 632 13 24 citations h-index g-index papers 46 46 46 1140 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Are patients benefiting from participation in the German skin cancer screening programme? A large cohort study based on administrative data. British Journal of Dermatology, 2022, 186, 69-77.	1.5	20
2	The Clinical Complexity of Penile Cancer: Current Clinical-Epidemiological Data from the Database of the Free State of Saxony/Germany. Urologia Internationalis, 2022, 106, 706-715.	1.3	3
3	Exploring relationships between in-hospital mortality and hospital case volume using random forest: results of a cohort study based on a nationwide sample of German hospitals, 2016–2018. BMC Health Services Research, 2022, 22, 1.	2.2	54
4	Effect of clinical peer review on mortality in patients ventilated for more than 24 hours: a cluster randomised controlled trial. BMJ Quality and Safety, 2022, , bmjqs-2021-013864.	3.7	2
5	Effectiveness of the IQM peer review procedure to improve in-patient care—a pragmatic cluster randomized controlled trial (IMPRESS): study design and baseline results. Zeitschrift Fur Gesundheitswissenschaften, 2021, 29, 195-203.	1.6	6
6	Ranking of the most relevant hospital inpatient diagnoses by age and diagnostic group based on DRG statistics in Germany. Zeitschrift Fur Gesundheitswissenschaften, 2021, 29, 541-551.	1.6	2
7	Utilization of Interdisciplinary Tumor Boards for Sarcoma Care in Germany: Results from the PROSa Study. Oncology Research and Treatment, 2021, 44, 301-312.	1.2	13
8	Incidence trends of pediatric onset inflammatory bowel disease in the years 2000–2009 in Saxony, Germany–first results of the Saxon Pediatric IBD Registry. PLoS ONE, 2021, 16, e0243774.	2.5	13
9	Can we trust the standardized mortality ratio? A formal analysis and evaluation based on axiomatic requirements. PLoS ONE, 2021, 16, e0257003.	2.5	8
10	Medical Care and Survival of Soft-Tissue and Bone Sarcoma Patients: Results and Methodological Aspects of a German Subnational Cohort Study Based on Administrative Healthcare Data. Oncology Research and Treatment, 2021, 44, 103-110.	1.2	3
11	Implementation and Effectiveness of Novel Therapeutic Substances for Advanced Malignant Melanoma in Saxony, Germany, 2010–2020—Cohort Study Based on Administrative Data. Cancers, 2021, 13, 6150.	3.7	3
12	Trends in incidence and prevalence of type 1 diabetes between 1999 and 2019 based on the Childhood Diabetes Registry of Saxony, Germany. PLoS ONE, 2021, 16, e0262171.	2.5	10
13	Patient-Level and Hospital-Level Risk Factors for In-Hospital Mortality in Patients Ventilated for More Than 24 Hours: Results of a Nationwide Cohort Study. Journal of Intensive Care Medicine, 2020, 36, 088506662094218.	2.8	4
14	Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000–2016. Cancers, 2020, 12, 2354.	3.7	8
15	Effectiveness of Global Treatment Budgets for Patients With Mental Disorders—Claims Data Based Meta-Analysis of 13 Controlled Studies From Germany. Frontiers in Psychiatry, 2020, 11, 131.	2.6	20
16	Ketoacidosis at onset of type 1 diabetes in children up to 14 years of age and the changes over a period of 18 years in Saxony, Eastern-Germany: A population based register study. PLoS ONE, 2019, 14, e0218807.	2.5	20
17	Ranking hospitals when performance and risk factors are correlated: A simulation-based comparison of risk adjustment approaches for binary outcomes. PLoS ONE, 2019, 14, e0225844.	2.5	5
18	Penile cancer – Incidence, mortality, and survival in Saxony, Germany. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 295.e1-295.e8.	1.6	16

#	Article	IF	Citations
19	Probability of hysterectomy in Germany. Revue D'Epidemiologie Et De Sante Publique, 2018, 66, S378.	0.5	O
20	The cost-effectiveness of interventions targeting lifestyle change for the prevention of diabetes in a Swedish primary care and community based prevention program. European Journal of Health Economics, 2017, 18, 905-919.	2.8	29
21	Trastuzumab and survival of patients with metastatic breast cancer. Archives of Gynecology and Obstetrics, 2017, 296, 303-312.	1.7	20
22	Incidence trends of type 1 diabetes before and after the reunification in children up to 14 years of age in Saxony, Eastern Germany. PLoS ONE, 2017, 12, e0183665.	2.5	17
23	Secondary malignant neoplasms among breast cancer patients in Germany: 1990 – 2013. , 2017, 79, .		0
24	Körperliche Bewegung, Übergewicht und Zervixkarzinom in Deutschland. Gesundheitswesen, 2017, 79, .	0.5	0
25	Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011. BMC Cancer, 2016, 16, 936.	2.6	27
26	Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1171-1182.	2.5	23
27	Impact of breast cancer subtypes and patterns of metastasis on outcome. Breast Cancer Research and Treatment, 2015, 150, 621-629.	2.5	157
28	Trends in Incidence Rates during 1999-2008 and Prevalence in 2008 of Childhood Type 1 Diabetes Mellitus in GERMANY – Model-Based National Estimates. PLoS ONE, 2015, 10, e0132716.	2.5	65
29	Health-related quality of life for pre-diabetic states and type 2 diabetes mellitus: a cross-sectional study in VÃsterbotten Sweden. Health and Quality of Life Outcomes, 2014, 12, 150.	2.4	37
30	Datenanalyse mit SAS®. , 2014, , .		9
31	Risk equations for the development of worsened glucose status and type 2 diabetes mellitus in a Swedish intervention program. BMC Public Health, 2013, 13, 1014.	2.9	10